Insulin-like growth factor (IGF) binding protein-1 (IGFBP-1) is generally believed to inhibit IGF action in the circulation. In contrast, IGFBP-1 has been reported to interact with cell surfaces and enhance IGF-I action locally in some tissues. Renal IGFBP-1 levels are found elevated in various conditions characterized by renal growth (e.g. diabetes mellitus, hypokalemia).
Introduction
The growth promoting effects of the growth hormone (GH)-insulin-like growth factor (IGF) axis on body and organ growth seem to be highly dependent on the distribution of the IGF binding proteins (IGFBPs). IGFBP-1, generally believed to inhibit IGF action in the circulation, has also been reported to interact with cell surfaces and enhance local IGF-I action (Jones & Clemmons 1995 , Lee et al. 1997 . In various conditions characterized by renal growth, renal IGFBP-1 levels have been reported to be elevated (e.g. diabetes mellitus, hypokalemia) (Flyvbjerg 1993 , Hsu et al. 1997 , van Neck et al. 1997 .
In man, circulating levels of IGFBP-1 are raised at short term in diabetes (Flyvbjerg 1993 , Fervenza et al. 1997 . In experimental diabetes in rodents, serum levels of IGFBP-1 are elevated as well, together with decreased IGF-I levels (Luo & Murphy 1992 , Bach et al. 1994 . In contrast, renal IGF-I concentrations are elevated despite an unchanged local production (Flyvbjerg et al. 1990 , Landau et al. 1995 , Raz et al. 1998 . However, in the renal cortex of diabetic rodents, IGFBP-1 mRNA is strongly increased (Landau et al. 1995) . Taken together, it is tempting to speculate that renal IGF-I is increased due to entrapment by IGFBP-1.
Potassium depletion also is characterized by a selective renal growth (Gustafson et al. 1973 , Flyvbjerg et al. 1991 .
In the hypertrophic kidneys of these animals, increased amounts of IGFBP-1 mRNA and protein were observed (Hsu et al. 1997 , Rohan et al. 1997 . This increase in renal IGFBP-1 mRNA expression in potassium-deficient rats was not affected by IGF-I infusion (van Neck et al. 1997) .
In order to test the renotropic effects of IGFBP-1 in an in vivo model, without compensatory feedback effects on GH secretion, IGFBP-1 was administered, alone or in combination with IGF-I, to Pit-1 deficient Snell dwarf mice. We have demonstrated that treatment of homozygous Snell dwarf mice with GH and IGF-I, for a period of 4 weeks, caused an increase in body length and body weight, whereas IGFBP-1 administration had no effect (van Buul-Offers et al. 2000) . Furthermore, GH, IGF-I and IGFBP-1 treatment also had a pronounced effect on kidney size. Although IGFBP-1 inhibited IGF-I induced total body growth, it further stimulated IGF-I induced kidney growth (van Buul-Offers et al. 2000) .
The aim of the present study was to investigate in further detail the renotropic effects of IGFBP-1, alone or in combination with IGF-I. In three control groups of Snell dwarf mice, placebo, GH or IGF-I was administered. We analyzed the effects of the different administrations on kidney morphology and kidney-specific mRNA and protein expression of the different members of the IGF system.
Materials and Methods

Test substances
E. coli-derived recombinant human IGF-I was kindly provided by Eli Lilly Co. (Indianapolis, IN, USA). Recombinant human GH was from Amersham-Pharmacia (Uppsala, Sweden). Human IGFBP-1 was purified as described previously (van Buul-Offers et al. 2000) from amniotic fluid from pregnant women (midterm) which was obtained for diagnostic purposes and approved by the institutional Ethics committee.
Animal experimentation
The experimental design has been described in detail previously (van Buul-Offers et al. 2000) . Briefly, in two independent long-term experiments, groups of Snell dwarf mice (males and females, aged 6-8 weeks and with identical mean lengths and weights at the start of the experiments) received GH (8·3 µg/day), IGF-I (30 µg/day), IGFBP-1 (105 µg/day), IGF-I+IGFBP-1 (30+105 µg/day) or PBS (control) for 4 weeks. In order to avoid hypoglycemia, 10% glucose was added to the drinking water, starting 1 week before the experiment. The dwarf mice (n=5 per group in each experiment) were injected s.c. in the neck with 0·1 ml hormone solution or vehicle, three times daily, 5 days a week. In this article we discuss the findings of the first experiment. However, the second experiment resulted in comparable findings. The study complied with Dutch regulations for care and use of laboratory animals.
Tissue isolation
Animals were killed 2 h after the last injection. Kidneys were removed and weighed to the nearest milligram, fixed overnight in 4% paraformaldehyde, and embedded in paraffin. Sections (4 µm) were cut and mounted on aminopropyl trioxysilane-coated slides. Slides were dried at 37 C for 3 days. In order to obtain optimal comparison between the different treatments, all organs were fixed, embedded in paraffin, and mounted on slides similarly and at the same time. Kidney sections of all groups have been mounted on the same slide. As a result, the experimental parameters of in situ hybridization and immunohistochemistry experiments per probe or antibody, respectively, were the same for all administration groups.
Morphology
To determine kidney size, the central sections from series of sagittal sections of kidneys were measured with a ruler. To count the number of nuclei per square, sections were placed under a light microscope with a grid. Per section 3 cortical areas were counted (=nuclei in a total area of 0·25 mm 2 ) of five animals per treatment group (=75 counts in total).
Cell proliferation
Human proliferating cell nuclear antigen (PCNA) was detected using anti-human PCNA (Roche Diagnostics, Almere, The Netherlands) in a dilution of 1:1000 and detected using the Vectastain peroxidase-conjugated elite ABC kit (Vector Laboratories, Burlingame, CA, USA).
Cell proliferation was estimated by determining the number of PCNA positive nuclei in central sections from series of sagittal sections of kidneys under a light microscope with a grid. Three sections were counted per animal of three animals per treatment group.
Probe preparation (in situ hybridization)
Specific mouse IGFBP cRNA probes were transcribed from IGFBP-2, -3, -4, -5, -6 cDNAs as described by Schuller et al. (1994) . The mouse cDNA Sph1-Sac1 fragment was used as template for the IGFBP-1 cRNA probe and was cloned into pTZ18R or pTZ19R (Pharmacia, Uppsala, Sweden) for the antisense and sense probes respectively. Similarly, mouse IGF-I and -II cDNAs (kindly provided by Dr G. I. Bell, Howard Hughes Institute, Chicago, IL, USA) fragments were subcloned into pTZ18 and pTZ19 (EcoRI for IGF-I and BamHI/Sac1 for IGF-II). A 265 bp EcoRI/Sma1 fragment of the rat type I IGF receptor cDNA ligated in PGEM3 (Promega, Madison, WI, USA) was kindly provided by Dr H. Werner and Dr D. LeRoith (National Institutes of Health, Bethesda, MD, USA) and was used as template for the type I IGF receptor probe. Digoxigenin-11-UTP labeled RNA probes were prepared according to the manufacturer's prescription (Boehringer Mannheim GmbH, Biochemica, Mannheim, Germany), using T7 or SP6 RNA polymerase.
In situ hybridization
A non-radioactive in situ hybridization was performed, as described previously (Lindenbergh-Kortleve et al. 1997) . In short, kidney sections from control and the four administration groups were mounted on the same glass slide and processed batch-wise. Hybridization was performed overnight at 55 C in a humid chamber in a hybridization solution containing 50% deionized formamide, 10% dextran sulfate, 2 SSC, 1 Denhardt's solution, 1 µg/ml tRNA, 250 µg/ml herring sperm DNA and the respective probes at a concentration of 100 ng/ml. After various washes (50% formamide/2 SSC, 50% formamide/1 SSC and 0·1 SSC) sections were incubated with RNase T1 (2 U/ml in 1 mM EDTA/2 SSC) for 15 min at 37 C. The digoxigenin-labeled hybrids were detected by antibody incubation performed according to the manufacturer's recommendations (Boehringer Mannheim GmbH, Biochemica, Mannheim, Germany). PVA (polyvinylalcohol, MW 31-50 kDa, Aldrich Chemical Co. Milwaukee, WI, USA) enhanced staining with BCIP (5-bromo-4-chloro-3-indolyl phosphate), NBT (4-nitroblue tetrazolium chloride) and levamisol was stopped when the desired intensity of the blue precipitate was reached. This was dependent on the relative abundance of the respective mRNAs. Sections were counterstained with Nuclear red solution and mounted with Euparal (Chroma Gesellschaft, Stuttgart, Germany). Control sections for morphological analysis were either stained with PAS, or with hematoxylin and eosin. In situ hybridized sections were analyzed blindly by two independent investigators, in at least five separate observations. Negative controls for in situ hybridization were performed using sense probes, which never gave any significant staining.
Immunohistochemistry
Polyclonal antisera to mIGFBP-1, -2, -3, -4, -5 and -6 were used that were previously described (van Kleffens et al. 1999) . Briefly, synthetic peptides (ID-DLO, Lelystad, the Netherlands), corresponding to parts of the variable region of the various mouse IGFBPs (IGFBP-1 and IGFBP-2: amino acid position (aa)174-189; IGFBP-3: aa200-213; IGFBP-4: aa155-170; , were coupled to the carrier keyhole limpet hemocyanin (KLH; Pierce, Rockford, IL, USA) and injected into rabbits. The resulting antisera were used in an immunohistochemical staining, making use of the peroxidase-anti-peroxidase (PAP) method. Specificity of the antisera was determined using ELISA, Western blotting and by verifying the staining patterns in normal versus gene-deletion mutant mice of the respective protein (van Kleffens et al. 1999) . The anti mIGFBP-1 and -3 polyclonal antisera were diluted 1:150, while the anti mIGFBP-2, -4, -5 and -6 polyclonal antisera were used in a dilution of 1:250. Staining patterns were analyzed in comparison to their respective preimmune sera, diluted 1:10. Unlabeled goat anti-rabbit immunoglobulins (Dako, Glostrup, Denmark; 1:50) were used as second antibody and rabbit PAP (Dako; 1:100) as a linker. Rabbit polyclonal antisera against type I IGFreceptor and goat polyclonal antisera against IGF-I and IGF-II (all with cross-reactivity to human, mouse and rat, according to the manufacturer) were obtained from Research Diagnostics Inc. (Flanders, NJ, USA) and used at a dilution of 1:200. The specificity of the type I IGFreceptor antibody was assured by blocking the antibodyreceptor binding using a control peptide for competition consisting of amino acids 31-50 of the human type I IGF-receptor as obtained from Research Diagnostics Inc. (Flanders). Staining was performed with diaminobenzidine (DAB; Fluka Chemika, Buchs, Switzerland; 0·75 mg/ml). Nuclei were made visible with Mayer's hematoxylin. Sections from control and all administration groups were mounted on the same glass slide and processed batch-wise.
Estimation of glomerular volume
A 2 mm thick horizontally cut slice from the middle of the kidney (containing the papilla) was fixed in 4% paraformaldehyde and embedded in Technovit. Then, 2 µm thick sections were cut on a rotation microtome and stained with p-aminosilacylic acid and hematoxylin. Mean glomerular tuft volume (V G ) was determined from the mean glomerular cross-sectional area (A G ) by light microscopy as previously described . Profile areas were traced using a computer-assisted morphometric unit (Image Tool: University of Texas Health Science Center, San Antonio, TX, USA). A G was determined as the average area of a total of 40-80 glomeruli (tuft omitting the proximal tubular tissue within Bowman's capsule) and V G was calculated as
, where =1·38, which is the shape coefficient for spheres (the idealized shape of glomeruli), and =1·1, which is a size distribution coefficient .
Statistical analysis
The differences in kidney weight and glomerular volume after the different administration regimen were analyzed and expressed as mean ... For comparison of multiple groups we used ANOVA as described by Scheffé (1959) . Student's t-test was applied for testing differences between two groups. A P value equal or less than 0·05 was regarded as significant. Figure 1A shows the weights of the kidneys after 4 weeks of treatment, expressed as a percentage of the kidney weight of control animals. All treatment regimen significantly increased renal weight. The remarkable effects on the kidneys obtained with IGFBP-1 alone were significantly higher than with IGF-I alone (Pc0·05), whereas the combination of IGFBP-1 and IGF-I seemed to demonstrate an additive effect on renal weight increase.
Results
Kidney weight
Renal morphology
To investigate possible differences in renal morphology between untreated, phenotypically normal heterozygous (+/dw) and untreated homozygous Snell dwarf mice, PAS stained sections were examined. No differences in morphology could be detected. Although kidneys of homozygous Snell dwarf mice were smaller, they were proportional to their decreased body size (results not shown). To examine the effects of the different administration regimen on the glomeruli, the glomerular volume was measured in all groups. Compared with placebo control kidneys, glomerular volume did not change significantly, although a tendency to increase could be observed in both the IGF-I and IGFBP-1/IGF-I groups (P=0·12 and P=0·11 respectively) (Fig. 1B) . shows the morphology of the dwarf mouse kidney. After treatment with IGFBP-1 (Fig. 2E ) and IGFBP-1+IGF-I (Fig. 2F) , kidneys of Snell dwarf mice demonstrated pronounced dilatation of thin limbs of Henle's loop in the medulla. This dilatation could not be observed in IGF-I (Fig. 2D ) and hGH (results not shown) treated mice. Regardless of the treatment, kidney weight increased simultaneously with kidney size. To determine if increased kidney weight reflected an increase in cell number, nuclei were counted in cortical areas. Kidney length and kidney weight were plotted against the number of cell nuclei per cortical area (Fig. 3) . In glomeruli, no changes in numbers of nuclei between the different treatment regimen were observed (data not shown). In the tubular cortical region and compared with control, a decreased number of nuclei per cortical area was found for all treatments, except for IGF-I. After treatment of IGF-I, kidney length and weight were increased, while the cell number per area did not change. In contrast, treatment of Snell dwarf mice with hGH, IGFBP-1 or IGF-I+ IGFBP-1 caused an increase in kidney length and weight, while the cell number per cortical area decreased simultaneously (Fig. 3) . Also, staining against the cell proliferation marker PCNA revealed an increased cell labeling 
index in the IGF-I treatment group only (results not shown).
Renal expression of the members of the IGF system
mRNA localization Table 1A shows the renal mRNA expression patterns of the members of the IGF system of the control mice. These were similar to those described previously for kidneys obtained from normal BALB/c mice (Lindenbergh-Kortleve et al. 1997) . mIGFBP-1 and mIGFBP-6 mRNA expression was very weak in kidneys of all administration groups and no differences were observed between the various administration modalities (results not shown). In Figs 4 and 5, representative mRNA expression patterns for the type I IGF-receptor, the IGFs and the IGFBPs of kidneys from GH, IGF-I, IGFBP-1 and IGFBP-1+IGF-I administered mice are shown, in order to illustrate the data used for Table 1B where differences, as compared with controls, are given, based on the screening of five animals for each treatment.
Control
In kidneys of heterozygous normal and homozygous dwarf control mice, type I IGF receptor mRNA was localized in Bowman's capsule, distal and proximal tubules and thick limbs of Henle's loop (Fig. 4A) . IGF-I mRNA was located in Bowman's capsule, proximal and distal tubules, peritubular capillaries of the inner cortex and the medulla and thick limbs of Henle's loop (Fig. 5A) . Localization of IGF-II mRNA was found in Bowman's capsule, distal and proximal tubules and thick limbs of Henle's loop (Fig. 5B ). IGFBP-2 mRNA was observed in the cortex in Bowman's capsule, thick limbs of Henle's loop, distal tubules and to a lesser extent in proximal tubules (Fig. 5C ). In the medulla, IGFBP-2 hybridization signals were found in the thick and thin limbs of Henle's loop (results not shown). Localization of IGFBP-3 mRNA was confined to peritubular capillaries of the outer cortex and the medulla (results not shown). Hybridization signals for IGFBP-4 mRNA were found in mesangial cells of glomeruli, proximal tubules, cortical thick limbs of Henle's loop and in peritubular capillaries of both the cortex and outer medulla (results not shown). IGFBP-5 mRNA was localized in the cortex in mesangial cells of glomeruli, juxtaglomerular cells, distal tubules and in peritubular capillaries of the outer cortex and medulla (Fig. 5G) .
GH administration
In GH-administered dwarf mice, renal expression of the type I IGF-receptor mRNA was increased in distal tubules (Fig. 4B) . Also IGFBP-2 mRNA expression was increased in the inner cortex in distal tubules (results not shown).
IGF-I administration IGF-system mRNA expression in kidneys of IGF-I administered dwarf mice was largely comparable to kidneys from control animals (results not shown). Only IGFBP-2 mRNA expression was more pronounced in distal tubules and cortical thick limbs of Henle's loop (results not shown).
IGFBP-1 administration IGFBP-1 administration revealed important changes in renal IGF-system mRNA expression. Type I IGF receptor mRNA expression was increased in the cortex in proximal tubules and in the thick limbs of Henle's loop (Fig. 4C) . IGF-I mRNA expression was increased in the thick limbs of Henle's loop 
in both cortex and medulla (Fig. 5D) . Similarly, staining of IGF-II mRNA was enhanced in cortical thick limbs of Henle's loop (Fig. 5E ). Increased IGFBP-2 mRNA signal was found in distal tubules of the cortex (results not shown). Furthermore, the number of epithelial cells from distal tubules that demonstrated IGFBP-5 mRNA expression was increased after IGFBP-1 treatment (Fig. 5J) .
IGFBP-1+IGF-I administration
Combined administration of IGFBP-1+IGF-I demonstrated elevated type I IGF receptor mRNA signals in the thick limbs of Henle's loop (Fig. 4D ). IGFBP-2 mRNA expression was elevated in Bowman's capsule and in distal tubules (Fig. 5F ).
Protein localization
Results of immunohistochemistry of kidneys of the different groups are summarized in Table 2A . Representative expression patterns for the type I IGF-receptor and the IGFBPs (Figs 4 and 5) of kidneys from GH, IGF-I, IGFBP-1 and IGFBP-1+IGF-I administered mice are shown, in order to illustrate the data used for Table 2B where differences, as compared with controls, are given based on the screening of five animals for each treatment. IGF-I, -II, IGFBP-1 and -6 could not be detected immunohistochemically.
Control
The kidneys of control dwarf mice revealed type I IGF receptor protein localization in proximal tubules, distal tubules and in thick limbs of Henle's loop in cortex and medulla (Fig. 4E ). IGFBP-2 protein was detected in proximal tubules and thick and thin limbs of Henle's loop (Fig. 5I ). IGFBP-3 protein was localized in peritubular capillaries of both the cortex (Fig. 4I ) and the outer medulla. IGFBP-4 localization was demonstrated in mesangial cells in the glomeruli, in proximal tubules and in thick and thin limbs of Henle's loop (Fig. 4K) . IGFBP-5 staining was weak and could be confined to proximal tubules (Fig. 5H) .
GH administration When comparing the GH infused group with the control group, renal type I IGF receptor staining was more intense in proximal tubules and cortical thick limbs of Henle's loop (Fig. 4F) . All other members of the IGF system showed identical staining patterns as in kidneys of control animals ( Table 2) .
IGF-I administration
Compared with controls, IGF-I administration did not result in any difference in staining patterns for the IGF system members that were tested as is illustrated for type I IGF receptor (results not shown).
IGFBP-1 administration
Type I IGF receptor protein staining was decreased in proximal and distal tubules and in thick limbs of Henle's loop (Fig. 4G) . Compared with the control group, IGFBP-3 staining was decreased in peritubular capillaries in both cortex and medulla (Fig. 4J) . IGFBP-4 staining was increased in the brush border of proximal tubules (Fig. 4L) . IGFBP-5 showed a more intense staining in distal tubules (Fig. 5K) .
IGFBP-1+IGF-I administration
The staining patterns of the IGF system components after combined IGFBP-1+ IGF-I treatment largely resembled the patterns found after IGFBP-1 treatment, except for IGFBP-2 that was decreased in proximal tubules and the thick limbs of Henle's loop (Fig. 5L) . Comparable to the IGFBP-1 administered group, type I IGF receptor protein staining was strongly decreased in proximal and distal tubules and in thick limbs of Henle's loop (Fig. 4H ). IGFBP-3 staining was decreased in peritubular capillaries in both cortex and medulla, IGFBP-4 staining was increased in the brush border of proximal tubules and IGFBP-5 showed a more intense staining in proximal and distal tubules (results not shown).
Discussion
In our previous study we have demonstrated that treatment of homozygous Snell dwarf mice with GH and IGF-I, for a period of 4 weeks, caused an increase in body length and body weight (van Buul-Offers et al. 2000) . GH, IGF-I and IGFBP-1 treatment also had a pronounced effect on kidney size. Although IGFBP-1 inhibited IGF-I induced total body growth, it further stimulated IGF-I induced kidney growth (van Buul-Offers et al. 2000) . In this study we investigated the renotropic effects of IGFBP-1 in further detail.
Effects of GH, IGF-I and/or IGFBP-1 on kidney morphology
In the present study the effects of GH, IGF-I, IGFBP-1 and IGFBP-1+IGF-I administration on the morphology and the expression pattern of members of the IGF system in kidneys of Snell dwarf mice were analyzed. Although an increased wet weight of the kidneys was observed in all treatment groups, when compared with controls, the morphology was different. When IGFBP-1, alone or in combination with IGF-I, was administered, fluid filled dilatations of thin limbs of Henle's loop were observed. This increased kidney weight occurred with a decreased mean number of nuclei per cortical area. Thus, we may conclude that short-term IGFBP-1 or IGF-I+IGFBP-1 treatment affected renal intracellular fluid accumulation and not cellular proliferation, as supported by an unchanged proliferation labeling index. This in contrast with treatment with IGF-I alone resulting in enlarged kidney size, due to enhanced kidney cell growth.
This study is comparable with a previous study by van Buul-Offers and co-workers (1995) , where the effects of IGFBP-3 and IGF-I, alone and in combination, were investigated on total body and organ growth. In contrast to IGFBP-1, IGFBP-3 inhibited IGF-I induced kidney growth, whereas administration of IGFBP-3 alone did not affect kidney size. In retrospect, we also observed no differences in morphology of the IGFBP-3 treated kidneys compared with the controls (data not shown). These findings might indicate different functions for IGFBP-1 and IGFBP-3 in the kidney.
The renal effects of IGFBP-1 administration in our present study seemed to be in contrast with observations in transgenic mouse models that overexpress IGFBP-1. In transgenic animals overexpressing IGFBP-1 under control of the metallothionein or phosphoglycerate promoter, no gross changes in kidney size and morphology were described (Dai et al. 1994 , Murphy et al. 1995 . It must be mentioned that in these transgenic animals elevated circulatory IGFBP-1 levels were not observed. In contrast, transgenic animals overexpressing IGFBP-1 under control of the liver-specific 1-antitrypsin promoter demonstrated a marked increase in the mesangial extracellular matrix. However, the total glomerular volume was not increased, suggesting that these IGFBP-1 transgenic animals developed glomerulosclerosis without glomerular hypertrophy (Doublier et al. 2000) .
In the present study, administration of GH or IGF-I to the Snell dwarf mice resulted in enlarged kidneys, confirming previous reports (Hirschberg 1993 , van BuulOffers et al. 1995 . Overexpression of GH and/or IGF-I in transgenic mice affected renal morphology (Quaife et al. 1989 , Wanke et al. 1991 . This, however, differed from the observations in our study. Kidneys of GH transgenic mice showed glomerulosclerosis and tubular cysts (Brem et al. 1989 ) whereas in our study no effects on kidney morphology were seen. These differences might be explained by the fact that in the transgenic animals, circulating levels of GH were pharmacologically high whereas in our (dwarf) model we used substitution doses (Brem et al. 1989) . Supranormal levels of IGF-I in transgenic animals resulted in enlarged glomeruli (Quaife et al. 1989) . The circulating IGF-I levels of these transgenic mice and of the IGF-I-treated dwarf mice in our study were comparable (540 and 417 µg/l respectively) (Mathews et al. 1988 , van Buul-Offers et al. 2000 , although the transgenic animals have constant circulatory IGF-I levels whereas in our study IGF-I was administered three times per day, for 4 weeks. Interestingly, also in our study, a tendency towards an increase in glomerular volume was observed. We only can speculate about the mechanisms of the tubular effects of IGFBP-1, which is solely observed in groups that received IGFBP-1, either alone or in combination with IGF-I and is not seen in the IGF-I administration group. It can be hypothesized that, under normal circumstances, circulatory IGF-I, when it is predominantly bound to IGFBP-3, does not leave the glomerular capillary network. In contrast, when IGFBP-1 is present abundantly, IGFBP-1/IGF-I complexes will be formed and transported from the glomerular capillary network into the tubular system. Here, IGFBP-1 determines the tubular bioavailability for the IGFs. This hypothesis is favored by a body of experimental evidence. First, the renal morphological effects of prolonged IGF-I overexpression in transgenic animals only are limited to glomerular hypertrophy (Doi et al. 1990 ). In addition, IGF-I administration, both in the human and in experimental animals, had direct effects on glomeruli where it increased renal plasma flow and glomerular filtration rate with a concomitantly decreased vascular resistance (Feld & Hirschberg 1996a) . Furthermore, in hypokalemia, increased renal IGFBP-1 mRNA and increased immunoreactive IGFBP-1 has been observed, which is spatially associated with tubular hyperplasia (Hsu et al. 1997 , Rohan et al. 1997 , van Neck et al. 1997 . These results suggest that IGFBP-1/IGF-I might play a major role in distal nephron adaptation.
Whether the effects of IGFBP-1 are IGF-I dependent or independent needs to be further elucidated. In this respect, a role for IGFBP-1 has been suggested in a streptozotocin induced diabetes model (Landau et al. 1995 , Feld & Hirschberg 1996b , Raz et al. 1998 , Segev et al. 1999 . Feld & Hirschberg (1996b) suggested that IGFBP-1 may have a stimulating effect on kidney growth, independent of IGF-I, through mitogenic actions via in the thick limbs of Henle's loop. These may play an important role in the onset of fluid accumulation and/or formation of dilatated thin limbs of Henle's loop. Furthermore, IGFBP-5 levels in the proximal tubules were found to be increased whereas IGFBP-3 levels in the peritubular capillaries and type I IGF receptor levels in the distal/ collecting tubules were decreased. However, we can not exclude that the changes in IGF system protein expression are not sufficient to induce the observed fluid accumulation and/or dilatation of the thin limbs of Henle's loop. Therefore, we suggest that a complex network of interacting factors may be implicated in this process.
In summary, we have shown that treatment with IGFBP-1 and IGFBP-1+IGF-I of Snell dwarf mice causes specific morphological changes in the kidney. Furthermore, specific alterations on mRNA as well as on protein levels of the IGF system occur. We suggest that IGFBP-1, directly or by regulating IGF bioavailability, may affect renal fluid exchange and/or increase hydrostatic pressure that may cause dilatations of the thin limbs of Henle's loop. Hence, our study provides a framework for a further understanding of the role of IGFBP-1 in renal physiology.
